Targeted drug combo tested for Tough-to-Treat cancers
NCT ID NCT05588609
Summary
This study tested a drug called zenocutuzumab, combined with other cancer medications, for people with two specific advanced cancers. It aimed to see if the combinations could help control tumors in patients with a certain genetic change (NRG1+) in their lung cancer or in men whose prostate cancer had stopped responding to standard hormone therapy. The trial was stopped early after enrolling only 13 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Florida Cancer Specialists
Lake Mary, Florida, 32746, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Northwest Medical Specialties
Tacoma, Washington, 98405, United States
-
The Center for Cancer and Blood Disorders
Bethesda, Maryland, 20817, United States
-
The Oncology Institute of Hope & Innovation
Whittier, California, 90603, United States
-
TriHealth Cancer Institute
Cincinnati, Ohio, 45220, United States
-
University Hospitals - Seidman Cancer Center
Cleveland, Ohio, 44106, United States
Conditions
Explore the condition pages connected to this study.